Herbal interactions involving cytochrome P450 enzymes: A mini review

Toxicological Reviews

Volumn 23, Issue 4, 2004, Pages 239-249

  Delgoda, Rupika ^a   Westlake, Andrew C G ^b  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGELICA SINENSIS EXTRACT; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEBRISOQUINE; DIAZEPAM; ERYTHROMYCIN; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; ISONIAZID; KAVA EXTRACT; KETOCONAZOLE; MEPHENYTOIN; NICOTINE; PARACETAMOL; ROSMARINUS OFFICINALIS EXTRACT; SPARTEINE; TAMOXIFEN; TERFENADINE; UNINDEXED DRUG;

ACUTE TOXICITY; ALCOHOL CONSUMPTION; AMINO ACID SEQUENCE; CIGARETTE SMOKING; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME STRUCTURE; ETHNIC DIFFERENCE; FOOD DRUG INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HERB DRUG INTERACTION; HUMAN; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; RACE DIFFERENCE; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL;

ALLIUM SATIVUM; PANAX GINSENG;

EID: 22544450860     PISSN: 11762551     EISSN: None     Source Type: Journal    
DOI: 10.2165/00139709-200423040-00004     Document Type: Review

References (117)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. In: Li AP, editor. Drug-drug interactions. London: Scientific and Regulatory Perspectives, 1997: 7-35
3. Cheng JW. Cytochrome P450 mediated cardiovascular drug interactions. Heart Dis 2000; 2: 254-8
4. Guengerich F. Role of cytochrome P450 enzymes in drug-drug interactions. In: Li AP, editor. Drug-drug interactions: scientific and regulatory perspectives. Adv Pharmacol 1997, 7-35
5. Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Devel 2002; 4: 45-54
6. Thompson T. Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans and a strategy for their use. In: Li A, editor. Drug-drug interactions. London: Scientific and Regulatory Perspectives, 1997: 205-29
7. Rodrigues AD. Use of in-vitro human metabolism studies in drug development. Biochem Pharmacol 1994; 48: 2147-56
8. Rodrigues AD, Wong S. Application of human liver microsomes in metabolism based drug drug interactions: in vitro-in vivo correlations and the Abbott laboratories experience. In: Li A, editor. Drug-drug interactions. London: Scientific and Regulatory Perspectives, 1997: 65-101
9. Guengerich FP, Shimada T, Bondon A, et al. Cytochrome P-450 oxidations and the generation of biologically reactive intermediates. Adv Exp Med Biol 1991; 283: 1-11
10. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41: 605-8
11. Guengerich FP. Roles of cytochrome P450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 1988; 48: 2946-54
12. Kirton SB, Baxter CA, Sutcliffe MJ. Comparative modelling of cytochrome P450. Adv Drug Deliv Rev 2002; 54: 385-406
13. Modi S, Paine MJ, Sutcliff MK, et al. A model for human cytochrome P450 2D6 based homology modeling and NMR studies of substrate binding. Biochemistry 1996; 35: 4540-50
14. Lewis F, Bird M, Dickins M, et al. Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform. Xenobiotica 2000; 30: 1-25
15. Ekins S, De Groot M, Jones J. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001; 29: 936-44
16. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320
17. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000; 143: 923-9
18. Keeney D, Waterman M. Regulation of steroid hydroxylase gene expression: importance to physiology and disease. Pharmacol Ther 1993; 58: 301-17
19. Miller W, Morel Y. The molecular genetics of 21-hydroxylase deficiency. Annu Rev Genet 1989; 23: 371-93
20. Nelson D. Cytochrome P450 homepage [online]. Available from URL: http://drnelson.utmem.edu/CytochromeP450.html [Accessed 2005 Apr 3]
21. Nelson D, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42
22. Guengerich F. Human cytochrome P450 enzymes. In: Ortiz de Montellano P, editor. Cytochrome P450. 2nd ed. New York: Plenum Press, 1995: 473-575
23. Guengerich F. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
24. Porter T. The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 2002; 16: 311-6
25. Cosme J, Johnson EF. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme: mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 2000; 275: 2545-53
26. Williams P, Cosme J, Sridhar V, et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000; 5: 121-31
27. Scott E, He Y, Wester M, et al. An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proc Natl Acad Sci U S A 2003; 100: 13196-201
28. Williams P, Cosme J, Ward A, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464-8
29. Williams PA, Cosme J, Vinkovic DM, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305: 683-6
30. Yano KJ, Wester MR, Schoch GA, et al. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-angstrom resolution. J Biol Chem 2004; 279: 38091-4
31. Shapiro L, Shear N. Drug interactions: proteins, pumps and P450s. J Am Acad Dermatol 2002; 4: 467-84
32. Crespi CL, Miller VP, Penman BW. Microtitre plate assays for inhibition of human, drug metabolising cytochromes P450. Anal Biochem 1997; 248: 188-90
33. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96
34. Hughes HB. On the metabolic fate of isoniazid. J Pharmacol Exp Ther 1953; 109: 444-52
35. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964; 63: 394-403
36. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-43
37. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
38. Wennerholm A, Johansson I, Massele AY, et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999; 9: 707-14
39. Masimirembwa C, Johansoon I, Hasler J, et al. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-80
40. Kidd R, Curry T, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African American exhibiting toxcitiy to phenytoin. Pharmacogenetics 2001; 11: 803-8
41. Scordo M, Aklillu E, Yaser U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50
42. Johnson JA, Herring VL, Wolfe MS, et al. CYP1A2 and CYP2D6 4-hydroxylate Propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294: 1099-105
43. Bapiro TE, Hasler JA, Ridderström M, et al. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant, potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharm 2002; 64: 1387-98
44. Shimizu T, Ochiai H, Åsell F, et al. Bioinformatics research on inter-racial differences in drug metabolism I: analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18: 48-70
45. Shimizu T, Ochiai H, Åsell F, et al. Bioinformatics research on inter-racial differences in drug metabolism II: analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes. Drug Metab Pharmacokinet 2003; 18: 71-8
46. Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim Biophys Acta 2003; 1619: 283-90
47. Piver B, Berthou F, Dreano Y, et al. Differential inhibition of human cytochrome P450 enzymes by e-viniferin, the dimer of resveratrol: comparison with resveratrol and polypheols from alcoholized beverages. Life Sci 2003; 73: 1199-213
48. Fraser HS, Dotson OY, Howard L, et al. Drug metabolizing capacity in Jamaican cigarette and marijuna smokers and non smokers. West Indian Med J 1983; 32: 207-11
49. Prior TI, Chue PS, Tibbo P, et al. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9 (4): 301-9
50. World Health Organization. WHO substance dependence [online]. 2000. Available from URL: http://www.who.int/substance_abuse/facts/cannabis/en/.html [Accessed 2005 Apr 8]
51. Hope Enterprises Ltd. National household survey of drug use and abuse in Jamaica 2001. Kingston: National Council of Drug Abuse, 2002; Nov: 78-9
52. Soyibo K, Lee MG. Use of illicit drugs among high-school students in Jamaica. Bull World Health Organ 1999; 77: 258-61
53. Miller G, Guengerich F. Binding and oxidation of alkyl 4-nitrophenol ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. Biochemistry 2001; 40: 7262-72
54. Hutzler J, Wienkers L, Wahlstrom J, et al. Activation of cytochrome 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 2003; 410: 16-24
55. Taylor M, Lamb D, Cannell R, et al. Cytochrome P450105D1 from Streptomyces griseus: heterologous expression, activity, and activation effects of multiple xenobiotics. Biochem Biophys Res Commun 1999; 263: 838-42
56. Flexner C, Acosta EP, Piscitelli SC. Drug-drug interactions to watch for [online]. Available from URL: http://www.prn.org/images/prn_nb_cntnt_images/ vol3num3/drug300dpi_600px_w.gif [Accessed 2005 Apr 8]
57. Flockhart DA. Cytochrome P450 drug interactions table [online]. Georgetown University Medical Centre. Available from URL: http://medicine.iupui. edu/flockhart/table.htm [Accessed 2005 Apr 8]
58. Kronbach T, Fischer V, Meyer UA. Cyclosporin metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporin metabolizing enzyme explains interactions of cylcosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5
59. Kivisto KY, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994; 27: 1-5
60. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquine. Clin Pharmacol Ther 1996; 60: 512-21
61. Sorensen JM. Herb-drug, food-drug, nutrient-drug and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8: 293-308
62. Di Marco MP, Edwards DJ, Wainder IW, et al. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002; 71: 1149-60
63. Desta Z, Soukhova N, Flockhart DA. Inhibition of cytochrome P450 isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45: 382-92
64. Jeppensen U, Loft S, Poulsen HE, et al. A fluvoxamine-caffeine interaction. Pharmacogenetics 1996; 6: 3213-22
65. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127-53
66. Neal JM, Kunze KL, Levy RH, et al. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003; 31: 1043-8
67. Long L, Dolan ME. Role of cytochrome P450 isoenzymes in metabolism of O6-benylguanine: implications for dacarbazine activation. Clin Cancer Res 2001; 7: 4239-44
68. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450(CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase(GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 165: 171-7
69. Smith G, Stanley LA, Sim E, et al. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25: 27-66
70. Kadlubar FF, Butler MA, Kaderlik KR, et al. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 1992; 98: 69-74
71. Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP1A and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999; 117: 189-98
72. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98
73. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451-78
74. Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10: 163-9
75. Zhou S, Koh H-L, Gao Y, et al. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004; 74: 935-68
76. Izzo A. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42: 139-48
77. Butterveck V, Derendorf H, Gaus W, et al. Pharmacokinetic herb-drug interactions: are preventive screening necessary and appropriate? Planta Med 2004; 70: 784-91
78. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-87
79. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's Wort and cyclosporin. Ann Pharmacother 2000; 34: 1013-6
80. Wang L, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191-7
81. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500-2
82. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604
83. Zou L, Hrakey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-89
84. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95
85. Guyonnet D, Belloir C, Suschetet M, et al. Liver subcellular fractions from rats treated by organosulfur compounds from allium modulate mutagen activation. Mutat Res 2000; 466: 17-26
86. Nguyen T, Villard P, Barlatier A, et al. Panax vietnamensis protects mice against carbon tetrachloride-induced hepatotoxicity without any modification of CYP2E1 gene expression. Planta Med 2000; 66: 714-9
87. Foster B, Vandenhoek S, Li KY, et al. Effects of several Chinese health products on human cytochrome P450 enzymes. J Pharm Pharm Sci 2002; 52: 185-9
88. Henderson G, Harkey M, Gershwin M, et al. Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999; 65: 209-14
89. Kang M, Won S, Park S, et al. Piperine effects on the expression of P4502E1, P4502B and P4501A in rat. Xenobiotica 1994; 24: 1195-204
90. Paolini M, Barillari J, Broccoli M, et al. Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 1999; 145: 35-42
91. Paolini M, Pozzetti L, Sapone A, et al. Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 1998; 62: 571-82
92. Ueng YF, Don MJ, Peng HS, et al. Effects of Wu-chu-yu-tang and its component herbs on drug metabolising enzymes. Jpn J Pharmacol 2002; 89: 267-73
93. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001; 53: 1323-9
94. Umegaki K, Saito K, Kubota Y, et al. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol 2002; 90: 345-51
95. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002; 30: 1153-7
96. Gorski J, Huang S, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89-100
97. Yue Q, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 2000; 355: 576-7
98. Piscitelli S, Burnstein A, Chaitt D, et al. Indinavir concentrations and St. John's wort. Lancet 2000; 355: 547-8
99. Piscitelli S, Burstein A, Weldon N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2001; 34: 234-8
100. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4: 176-84
101. Bano G, Raina R, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 615-7
102. Jones B, Runikis A. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987; 7: 201-2
103. Ohnishi N, Kusuhara M, Yoshioka M, et al. Studies on interaction between functional foods or dietary supplements and medicines I: effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 2003; 26: 1315-20
104. Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004; 56: 1039-44
105. Ishihara K, Kushida H, Yuzurihara M, et al. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol 2000; 52: 1023-9
106. Debersac P, Vernevaut MF, Amiot MJ, et al. Effects of a water soluble extract of rosemary and it purified component rosmarinic acid on xenobiotic metabolizing enzymes in rat liver. Food Chem Toxicol 2001; 39: 109-17
107. Srivastava S. The toxicology of plant products of medicinal value. In: Mansingh A, Young R, Yee T, et al., editors. Proceedings of the International Symposium on Utilization of Natural Products in Developing Countries: trends and needs; 2000 Jul 9-14; Jamaica, 77-83
108. Munasinghe T. Adverse drug reactions: monitoring, reporting and prevention. Ceylon Med J 2002; 47: 19-21
109. Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology 2002; 181-182: 103-7
110. Fernandopulle RB, Weerasuriya K. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Saf 2003; 26: 219-25
111. van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26: 211-7
112. Eisenberg D. Unconventional medicine in the United States: prevalence, costs and the patterns of use. N Engl J Med 1993; 328: 246-52
113. Bent S, Richard K. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-85
114. Harnack L, Rydell S, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc 2001; 76: 688-94
115. World Health Organization. Traditional medicine [fact sheet no. 134]. Geneva: WHO, revised 2003
116. Kaufman D, Kelly J, Rosenburg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44
117. Delgoda R, Ellington C, Barrett S, et al. The practice of polypharmacy involving herbal and prescription medicines in the treatment of diabetes, hypertension and gastro-intestinal tract disorders in Jamaica. West Ind Med J 2004; 53: 400-5